IJERPH, Vol. 16, Pages 4794: Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
In conclusion, our data suggest that dose-dense weekly paclitaxel (80 mg/m2) combined with low-dose triweekly cisplatin (20 mg/m2) is a potentially effective and highly tolerable front-line treatment in advanced EOC, FTC, and PPSC. Randomized trials comparing the outcome of this regimen to other standard therapies for FIGO stage IIIC–IV EOC, FTC, and PPSC are warranted.
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Min Cheng Howard Hao Lee Wen-Hsun Chang Na-Rong Lee Hsin-Yi Huang Yi-Jen Chen Huann-Cheng Horng Wen-Ling Lee Peng-Hui Wang Tags: Article Source Type: research
More News: Anemia | Brain | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Environmental Health | Epithelial Cancer | Fallopian Tube Cancer | International Medicine & Public Health | Neurology | Neurosurgery | OBGYN | Ovarian Cancer | Ovaries | Peripheral Neuropathy | Peritoneal Cancer | Serous Carcinoma | Thrombocytopenia | Women